Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 12/20 | 0.42 |
| ▸ | BRAF | P15056 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29083242 | 0.87 | KDR (0.52) | KDRBRAFMET | |
| SCHEMBL2551479 | 0.87 | GCK (0.56) | KMT2AGCKKDRBRAFLMNA | |
| SCHEMBL29788823 | 0.87 | GCK (0.56) | KMT2AGCKKDRBRAFLMNA | |
| SCHEMBL2550819 | 0.86 | GCK (0.42) | KMT2AGCKKDRBRAFP2RX3 | |
| SCHEMBL2557702 | 0.85 | GCK (0.44) | GCKKDRBRAFLMNAMET | |
| SCHEMBL29083255 | 0.84 | MEN1 (0.45) | KMT2AGCKKDRBRAFLMNA | |
| SCHEMBL29083236 | 0.84 | GCK (0.45) | GCKKDRBRAFMET | |
| SCHEMBL29083232 | 0.82 | ALDH1A1 (0.42) | KMT2AGCKKDRLMNAMET | |
| SCHEMBL29083248 | 0.82 | POLB (0.42) | KMT2AGCKKDRBRAFLMNA | |
| SCHEMBL13504178 | 0.80 | RAB9A (0.53) | KMT2AKDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907339-B | 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof | 成都奥睿药业有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-114907339-A | 4- (4-aminophenoxy) pyridin-2-amine derivatives and uses thereof | 成都奥睿药业有限公司 | 2022-08-16 | — | — | CN | disclosed |